Document:

EX-4.8

 Exhibit 4.8 

THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR AN OPINION OF COUNSEL SATISFACTORY TO THE
COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT. 
 CONVERTIBLE
PROMISSORY NOTE 
  

			
	 No. [    ]
	  	Date of Issuance
	 $[                    ].00
	  	November [    ], 2012

 FOR VALUE RECEIVED, GeNO, LLC, a Delaware limited liability company (the “Company”), hereby
promises to pay [                    ] (the “Holder”), the principal amount of
[                    ] Dollars ($
[                    ].00), together with interest on the Outstanding Principal from the date of this Note. Interest shall accrue on the Outstanding
Principal at the rate of ten percent (10.0%) per annum, compounded annually. Unless earlier converted into Conversion Shares pursuant to Section 2.1 of that certain Convertible Note Purchase Agreement dated as of November 2, 2012, by and
among the Company, Holder and certain other parties (as such agreement may be amended, supplemented or otherwise modified from time to time, the “Purchase Agreement”), the Outstanding Loan Amount shall be due and payable by the
Company at the Maturity Date. This Note is one of a series of Notes issued pursuant to the Purchase Agreement, and capitalized terms not defined herein shall have the meaning set forth in the Purchase Agreement. 

1. Payment. All payments under this Note shall be made in lawful money of the United States of America at the principal office of the
Company, or at such other place as the Holder hereof may from time to time designate in writing to the Company. Payment shall be credited first to Costs (as defined below), if any, then to accrued interest due and payable and any remainder applied
to Outstanding Principal. Prepayment of the Outstanding Loan Amount may not be made without the consent of the Majority Note Holders; provided, however, that if at least ninety percent (90%) of the Outstanding Loan Amount has been
prepaid in the form of cash or equity of the Company, the Company may prepay the remainder in cash without the consent of the Majority Note Holders. The Company hereby waives demand, notice, presentment, protest and notice of dishonor. 

2. Conversion of the Notes. This Note and any amounts due hereunder shall be convertible into Conversion Shares in accordance with the
terms of Section 2.1 of the Purchase Agreement. As promptly as practicable after the conversion of this Note, the Company at its expense shall issue and deliver to the Holder of this Note, upon surrender of the Note, a certificate or
certificates for the number of full Conversion Shares issuable upon such conversion. 

 3. Amendments and Waivers; Resolutions of Dispute; Notice. The amendment or waiver of any
term of this Note, the resolution of any controversy or claim arising out of or relating to this Note and the provision of notice shall be conducted pursuant to the terms of the Purchase Agreement. 

4. Successors and Assigns. This Note applies to, inures to the benefit of, and binds the successors and assigns of the parties hereto;
provided, however, that the Company may not assign its obligations under this Note without the written consent of the Majority Note Holders. Any transfer of this Note may be effected only pursuant to the Purchase Agreement and by
surrender of this Note to the Company and reissuance of a new note to the transferee. The Holder and any subsequent holder of this Note receives this Note subject to the foregoing terms and conditions, and agrees to comply with the foregoing terms
and conditions for the benefit of the Company and any other holders. 
 5. Officers and Managers Not Liable. In no event shall any
officer or manager of the Company be liable for any amounts due and payable pursuant to this Note. 
 6. Expenses. The Company hereby
agrees, subject only to any limitation imposed by applicable law, to pay all expenses, including reasonable attorneys’ fees and legal expenses, incurred by the Holder of this Note (“Costs”) in endeavoring to collect any amounts
payable hereunder which are not paid when due, whether by declaration or otherwise. The Company agrees that any delay on the part of the Holder in exercising any rights hereunder will not operate as a waiver of such rights. The Holder of this Note
shall not by any act, delay, omission or otherwise be deemed to have waived any of its rights or remedies, and no waiver of any kind shall be valid unless in writing and signed by the party or parties waiving such rights or remedies. 

7. Governing Law. This Note shall be governed by and construed under the laws of the State of Delaware (excluding the laws and rules of
law applicable to conflicts or choice of law). 
  

			
	GENO LLC
		
	By:	 	  

	Name:	 	David Fine, Chief Executive OfficerEX-4.9

 Exhibit 4.9 
 June 19, 2013                         

GeNO LLC 
 45 First Ave. 

Waltham, MA 02451 
  

	 	Re:	Additional Investment in GeNO 

 Gentlemen:

 The undersigned has agreed to provide additional funding to GeNO LLC (“GeNO”) on the terms and conditions applicable
to additional equity financing that GeNO plans to seek from third parties (the “New Equity Investment”). It is understood that the terms of the New Equity Investment have not yet been finalized. 

Additional funds advanced to GeNO by the undersigned on or after the date hereof shall be treated as loans to GeNO with interest at the
rate of ten percent (10%) per year, and the loan balances together with accrued interest, will be converted to equity in GeNO on the terms and conditions of the New Equity Investment at the time that the New Equity Investment is completed.

 Please indicate your agreement with the foregoing by signing the enclosed copy of this letter where indicated below and
returning it to the undersigned. 
  

			
	 Sincerely,
  

DHAG HOLDINGS, LLC

		
	By:	 	/s/ David H. Fine
		 	David H. Fine

 AGREED: 

GENO LLC 
  

			
	By:	 	/s/ Kurt A. Dasse
		 	Kurt A. Dasse, President

 August 12,
2013                     
 GeNO LLC

 45 First Ave. 
 Waltham, MA 02451

  

	 	Re:	Additional Investment in GeNO 

 Gentlemen:

 The amounts identified below shall be treated as loans to GeNO LLC from the dates indicated for the amounts advanced, as
contemplated by the letter agreement between GeNO and the undersigned dated June 19, 2013. 
  

					
	 Advance on 7/26/13:
	  	 	466,379.56	  
	 Interest on advance through 8/23/13
	  	 	3,577.71	  
	 July mortgage payment
	  	 	5,578.90	  
	 August mortgage payment
	  	 	5,578.90	  
		  	  
	  
	 
		  	 	481,115.07	  
		  	  
	  
	 

 Please indicate your agreement with the foregoing by signing the enclosed copy of this letter where
indicated below and returning it to the undersigned. 
  

			
	 Sincerely,
  

DHAG HOLDINGS, LLC

		
	By:	 	/s/ David H. Fine
		 	David H. Fine

 AGREED: 

GENO LLC 
  

			
	By:	 	/s/ Kurt A. Dasse
		 	Kurt A. Dasse, PresidentEX-4.10

 Exhibit 4.10 
 June 19, 2013                     
 GeNO LLC 
 45 First Ave. 
 Waltham, MA 02451 
  

	 	Re:	Additional Investment in GeNO 

 Gentlemen:

 The undersigned has agreed to provide additional funding to GeNO LLC (“GeNO”) on the terms and conditions applicable
to additional equity financing that GeNO plans to seek from third parties (the “New Equity Investment”). It is understood that the terms of the New Equity Investment have not yet been finalized. 

Additional funds advanced to GeNO by the undersigned on or after the date hereof shall be treated as loans to GeNO with interest at the
rate of ten percent (10%) per year, and the loan balances together with accrued interest, will be converted to equity in GeNO on the terms and conditions of the New Equity Investment at the time that the New Equity Investment is completed.

 Please indicate your agreement with the foregoing by signing the enclosed copy of this letter where indicated below and
returning it to the undersigned. 
  

			
	Sincerely,
		
		 	/s/ David H. Fine
		 	David H. Fine

 AGREED: 

GENO LLC 
  

			
	By:	 	/s/ Kurt A. Dasse
		 	Kurt A. Dasse, President

 August 12,
2013                     
 GeNO LLC

 45 First Ave. 
 Waltham, MA 02451

  

	 	Re:	Additional Investment in GeNO 

 Gentlemen:

 The amounts identified below shall be treated as loans to GeNO LLC from the dates indicated for the amounts advanced, as
contemplated by the letter agreement between GeNO and the undersigned dated June 19, 2013. 
  

					
	 Advance on 6/19/13:
	  	 	285,168.51	  
	 Interest on advance through 8/23/13
	  	 	5,078.34	  
	 Pay for 2 wks ended 7/12/13:
	  	 	15,878.82	  
	 Pay for 2 wks ended 7/26/13:
	  	 	15,878.82	  
	 Pay for 2 wks ended 8/9/13:
	  	 	15,878.82	  
	 Pay for 2 wks ended 8/23/13:
	  	 	15,878.82	  
	 July condo rent
	  	 	2,200.00	  
	 August condo rent
	  	 	2,200.00	  
		  	  
	  
	 
		  	 	358,162.13	  
		  	  
	  
	 

 Please indicate your agreement with the foregoing by signing the enclosed copy of this letter where
indicated below and returning it to the undersigned. 
  

			
	Sincerely,
		
		 	/s/ David H. Fine
		 	David H. Fine

 AGREED: 

GENO LLC 
  

			
	By:	 	/s/ Kurt A. Dasse
		 	Kurt A. Dasse, PresidentEX-4.11

 Exhibit 4.11 
 June 19, 2013                     
 GeNO LLC 
 45 First Ave. 
 Waltham, MA 02451 
  

	 	Re:	Additional Investment in GeNO 

 Gentlemen:

 The undersigned has agreed to provide additional funding to GeNO LLC (“GeNO”) on the terms and conditions applicable
to additional equity financing that GeNO plans to seek from third parties (the “New Equity Investment”). It is understood that the terms of the New Equity Investment have not yet been finalized. 

Additional funds advanced to GeNO by the undersigned on or after the date hereof shall be treated as loans to GeNO with interest at the
rate of ten percent (10%) per year, and the loan balances together with accrued interest, will be converted to equity in GeNO on the terms and conditions of the New Equity Investment at the time that the New Equity Investment is completed.

 Please indicate your agreement with the foregoing by signing the enclosed copy of this letter where indicated below and
returning it to the undersigned. 
  

			
	Sincerely,
		
		 	/s/ Kurt A. Dasse
		 	Kurt A. Dasse

 AGREED: 

GENO LLC 
  

			
	By:	 	/s/ David H. Fine
		 	David H. Fine, CEO

 August 12,
2013                     
 GeNO LLC

 45 First Ave. 
 Waltham, MA 02451

  

	 	Re:	Additional Investment in GeNO 

 Gentlemen:

 The amounts identified below shall be treated as loans to GeNO LLC from the dates of the amounts advanced, as contemplated by
the letter agreement between GeNO and the undersigned dated June 19, 2013. 
  

					
	 Advance on 6/19/13:
	  	 	200,000.00	  
	 Interest on advance through 8/23/13
	  	 	3,561.64	  
		  	  
	  
	 
		  	 	203,561.64	  
		  	  
	  
	 

 Please indicate your agreement with the foregoing by signing the enclosed copy of this letter where
indicated below and returning it to the undersigned. 
  

			
	Sincerely,
		
		 	/s/ Kurt A. Dasse
		 	Kurt A. Dasse

 AGREED: 

GENO LLC 
  

			
	By:	 	/s/ David H. Fine
		 	David H. Fine, CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]